The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 10, 2014, Pages 1822-1829

  Imura, Satoru ^a   Tovuu, Lkhagva Ochir ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Ikemoto, Tetsuya ^a   Arakawa, Yusuke ^a   Kanamoto, Mami ^a   Iwahashi, Shuichi ^a   Saito, Yu ^a   Takasu, Chie ^a   Yamada, Shinichiro ^a   Ishikawa, Daichi ^a   Bando, Yoshimi ^b   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carcinogenesis; Gene expression; Multicentric recurrence; Prognosis

Indexed keywords

CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; ONCOPROTEIN; UBIQUITIN PROTEIN LIGASE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTEIN DEGRADATION; RISK FACTOR; TUMOR RECURRENCE; UBIQUITINATION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; F-BOX PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS; PROGNOSIS; PROTEOLYSIS; RISK FACTORS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84911980621     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12623     Document Type: Article

References (47)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl. 4): 5-13.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Shimada M, Takenaka K, Gion T etal. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-726.
4. Utsunomiya T, Matsumata T, Adachi E, Honda H, Sugimachi K. Limitations of current preoperative liver imaging techniques for intrahepatic metastatic nodules of hepatocellular carcinoma. Hepatology 1992; 16: 694-701.
5. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
6. Takenaka K, Adachi E, Nishizaki T etal. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19: 889-894.
7. Kumada T, Nakano S, Takeda I etal. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
8. Iizuka N, Oka M, Yamada-Okabe H etal. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-929.
9. Kurokawa Y, Matoba R, Takemasa I etal. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J. Hepatol. 2004; 41: 284-291.
10. Kim JW, Ye Q, Forgues M etal. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004; 39: 518-527.
11. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006; 6: 369-381.
12. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008; 8: 83-93.
13. Koepp DM, Schaefer LK, Ye X etal. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294: 173-177.
14. Yada M, Hatakeyama S, Kamura T etal. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23: 2116-2125.
15. O'Neil J, Grim J, Strack P etal. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007; 204: 1813-1824.
16. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005; 8: 25-33.
17. Ibusuki M, Yamamoto Y, Shinriki S, Ando Y, Iwase H. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci. 2011; 102: 439-445.
18. Hagedorn M, Delugin M, Abraldes I etal. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 2007; 2: 9.
19. Kurashige J, Watanabe M, Iwatsuki M etal. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br. J. Cancer 2012; 106: 182-188.
20. Yokobori T, Mimori K, Iwatsuki M etal. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009; 69: 3788-3794.
21. Iwatsuki M, Mimori K, Ishii H etal. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int. J. Cancer 2010; 126: 1828-1837.
22. Grim JE, Knoblaugh SE, Guthrie KA etal. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol. Cell. Biol. 2012; 32: 2160-2167.
23. Ishikawa Y, Hosogane M, Okuyama R etal. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch. Oncogene 2013; 32: 1921-1932.
24. Welcker M, Orian A, Jin J etal. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. U. S. A. 2004; 101: 9085-9090.
25. Flügel D, Görlach A, Kietzmann T. GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α. Blood 2012; 119: 1292-1301.
26. Wang Z, Inuzuka H, Zhong J etal. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012; 586: 1409-1418.
27. Tu K, Zheng X, Zan X, Han S, Yao Y, Liu Q. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol. Res. 2012; 42: 904-910.
28. Tovuu LO, Imura S, Utsunomiya T etal. Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma. Int. J. Clin. Oncol. 2013; 18: 651-656.
29. Tovuu LO, Utsunomiya T, Imura S etal. The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int. J. Clin. Oncol. 2013. doi: 10.1007/s10147-013-0593-y
30. Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 1995-2004.
31. Utsunomiya T, Okamoto M, Wakiyama S etal. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann. Surg. Oncol. 2006; 13: 947-954.
32. Shimada M, Sugimoto K, Iwahashi S etal. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J. Gastroenterol. 2010; 45: 896-902.
33. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
34. Huppertz A, Haraida S, Kraus A etal. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478.
35. Bolondi L, Gaiani S, Celli N etal. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34.
36. Tan Y, Sangfelt O, Spruck C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett. 2008; 271: 1-12.
37. Onoyama I, Tsunematsu R, Matsumoto A etal. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 2007; 204: 2875-2888.
38. Rajagopalan H, Jallepalli PV, Rago C etal. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428: 77-81.
39. Kitagawa K, Hiramatsu Y, Uchida C etal. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene 2009; 28: 2393-2405.
40. Mao JH, Kim IJ, Wu D etal. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008; 321: 1499-1502.
41. Guo Z, Zhou Y, Evers BM, Wang Q. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem. Biophys. Res. Commun. 2012; 418: 426-432.
42. Babaei-Jadidi R, Li N, Saadeddin A etal. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 2011; 208: 295-312.
43. Welcker M, Singer J, Loeb KR etal. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 2003; 12: 381-392.
44. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori H. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J. Gastroenterol. 2010; 45: 146-152.
45. Iriuchishima H, Takubo K, Matsuoka S etal. Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7α overexpression. Blood 2011; 117: 2373-2377.
46. Matsumoto A, Onoyama I, Sunabori T, Kageyama R, Okano H, Nakayama KI. Fbxw7-dependent degradation of Notch is required for control of "stemness" and neuronal-glial differentiation in neural stem cells. J. Biol. Chem. 2011; 286: 13754-13764.
47. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013; 23: 347-361.